ddRNAi (DNA-directed RNAi) is a unique platform technology for silencing unwanted or disease-causing genes. In the context of therapy, ddRNAi avoids many of the drawbacks of other gene silencing technologies and produces much longer-lasting effects.
Benitec Biopharma pioneered ddRNAi and was the first company to demonstrate expressed RNAi in human cells. We hold a dominant intellectual property position in RNAi, with over 40 issued global patents for the human use of ddRNAi.
Learn how ddRNAi could target countless human and viral genes. Track our pipeline programs using this exciting technology. View the scope of our patents in ddRNAi. Join us in developing transformational solutions for human health.
Treatment & Cure
Learn how ddRNAi outperforms traditional RNAi approaches and avoids the pitfalls.
Track our progress towards
human trials of ddRNAi for chronic and life-threatening conditions.
April 10, 2014
Results of Meeting Read More
March 17, 2014
Lodge Partners maintains "Buy" recommendation, increasing target price to $3.20 Read More
February 24, 2014
Benitec announces $31.5M capital raise Read more